Abouhussein DMN, Khattab A, Bayoumi NA, Mahmoud AF, Sakr TM (2018) Brain targeted rivastigmine mucoadhesive thermosensitive In situ gel: optimization, in vitro evaluation, radiolabeling, in vivo pharmacokinetics and biodistribution. J Drug Deliv Sci Technol 43:129–140

Article  CAS  Google Scholar 

Adlimoghaddam A, Neuendorff M, Roy B, Albensi BC (2018) A review of clinical treatment considerations of donepezil in severe Alzheimer’s disease. CNS Neurosci Ther 24:876–888

Article  PubMed  PubMed Central  Google Scholar 

Agrawal M, Saraf S, Saraf S, Antimisiaris SG, Chougule MB, Shoyele SA, Alexander A (2018) Nose-to-brain drug delivery: an update on clinical challenges and progress towards approval of anti-Alzheimer drugs. J Control Release 281:139–177

Article  PubMed  CAS  Google Scholar 

Agu RU (2016) Challenges in nasal drug absorption: how far have we come? Ther Deliv 7:495–510

Article  PubMed  CAS  Google Scholar 

Alexander A, Saraf S (2018) Nose-to-brain drug delivery approach: a key to easily accessing the brain for the treatment of Alzheimer’s disease. Neural Regen Res 13:2102

Article  PubMed  PubMed Central  CAS  Google Scholar 

Alqahtani MS, Kazi M, Alsenaidy MA, Ahmad MZ (2021) Advances in oral drug delivery. Front Pharmacol 12:618411

Article  PubMed  PubMed Central  CAS  Google Scholar 

del Amo L, Cano A, Ettcheto M, Souto EB, Espina M, Camins A, García ML, Sánchez-López E (2021) Surface functionalization of PLGA nanoparticles to increase transport across the BBB for Alzheimer’s disease. Appl Sci 11:4305

Article  Google Scholar 

Antonell A, Balasa M, Oliva R, Lladó A, Bosch B, Fabregat N, Fortea J, Molinuevo JL, Sánchez-Valle R (2011) A novel PSEN1 gene mutation (L235R) associated with familial early-onset Alzheimer’s disease. Neurosci Lett 496:40–42

Article  PubMed  CAS  Google Scholar 

Association AS (2017) Alzheimer’s disease facts and figures. Alz Dementia 13:325–373

Google Scholar 

Attia MF, Anton N, Wallyn J, Omran Z, Vandamme TF (2019) An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites. J Pharm Pharmacol 71:1185–1198

Article  PubMed  CAS  Google Scholar 

Ausó E, Gómez-Vicente V, Esquiva G (2020) Biomarkers for Alzheimer’s disease early diagnosis. J Personalized Med 10:114

Article  Google Scholar 

Awad R, Avital A, Sosnik A (2023) Polymeric nanocarriers for nose-to-brain drug delivery in neurodegenerative diseases and neurodevelopmental disorders. Acta Pharmaceutica Sinica B 13:1866–1886

Article  PubMed  CAS  Google Scholar 

Bahadur S, Pathak K (2012) Buffered nanoemulsion for nose to brain delivery of ziprasidone hydrochloride: preformulation and pharmacodynamic evaluation. Curr Drug Deliv 9:596–607

Article  PubMed  CAS  Google Scholar 

Banerjee SS, Aher N, Patil R, Khandare J (2012) Poly(ethylene glycol)-prodrug conjugates: concept, design, and applications. J Drug Deliv 2012:103973

Article  PubMed  PubMed Central  Google Scholar 

Barrantes FJ, Borroni V, Vallés S (2010) Neuronal nicotinic acetylcholine receptor–cholesterol crosstalk in Alzheimer’s disease. FEBS Lett 584:1856–1863

Article  PubMed  CAS  Google Scholar 

Barthet G, Georgakopoulos A, Robakis NK (2012) Cellular mechanisms of γ-secretase substrate selection, processing and toxicity. Prog Neurobiol 98:166–175

Article  PubMed  CAS  Google Scholar 

Better MA (2023) Alzheimer’s disease facts and figures. Alz Dement 19:1598–1695

Google Scholar 

Blennow K (2005) CSF biomarkers for Alzheimer’s disease: use in early diagnosis and evaluation of drug treatment. Expert Rev Mol Diagn 5:661–672

Article  PubMed  CAS  Google Scholar 

Botti G, Bianchi A, Dalpiaz A, Tedeschi P, Albanese V, Sorrenti M, Catenacci L, Bonferoni MC, Beggiato S, Pavan B (2023) Dimeric ferulic acid conjugate as a prodrug for brain targeting after nasal administration of loaded solid lipid microparticles. Expert Opin Drug Deliv 20:1657–1679

Article  PubMed  CAS  Google Scholar 

Bourganis V, Kammona O, Alexopoulos A, Kiparissides C (2018) Recent advances in carrier mediated nose-to-brain delivery of pharmaceutics. Eur J Pharm Biopharm 128:337–362

Article  PubMed  CAS  Google Scholar 

Califf RM (2018) Biomarker definitions and their applications. Exp Biol Med 243:213–221

Article  CAS  Google Scholar 

Cervantes S, Samaranch L, Vidal-Taboada JM, Lamet I, Bullido MJ, Frank-García A, Coria F, Lleó A, Clarimón J, Lorenzo E, Alonso E, Sánchez-Juan P, Rodríguez-Rodríguez E, Combarros O, Rosich M, Vilella E, Pastor P (2011) Genetic variation in APOE cluster region and Alzheimer’s disease risk. Neurobiol Aging 32:2107.e7-2107.e17

Article  PubMed  Google Scholar 

Cheignon C, Tomas M, Bonnefont-Rousselot D, Faller P, Hureau C, Collin F (2018) Oxidative stress and the amyloid beta peptide in Alzheimer’s disease. Redox Biol 14:450–464

Article  PubMed  CAS  Google Scholar 

Cho SM, Lee S, Yang S-H, Kim HY, Lee MJ, Kim HV, Kim J, Baek S, Yun J, Kim D, Kim YK, Cho Y, Woo J, Kim TS, Kim Y (2016) Age-dependent inverse correlations in CSF and plasma amyloid-β(1–42) concentrations prior to amyloid plaque deposition in the brain of 3xTg-AD mice. Sci Rep 6:20185

Article  PubMed  PubMed Central  CAS  Google Scholar 

Cho HS, Huang LK, Lee YT, Chan L, Hong CT (2018) Suboptimal baseline serum vitamin B12 is associated with cognitive decline in people with Alzheimer’s disease undergoing cholinesterase inhibitor treatment. Front Neurol 9:325

Article  PubMed  PubMed Central  Google Scholar 

Crowe TP, Greenlee MHW, Kanthasamy AG, Hsu WH (2018) Mechanism of intranasal drug delivery directly to the brain. Life Sci 195:44–52

Article  PubMed  CAS  Google Scholar 

Deardorff WJ, Grossberg GT (2016) A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer’s disease. Drug des Dev Ther 10:3267–3279

Article  CAS  Google Scholar 

Dhas N, Mehta T (2021) Intranasal delivery of chitosan decorated PLGA core/shell nanoparticles containing flavonoid to reduce oxidative stress in the treatment of Alzheimer’s disease. J Drug Deliv Sci Technol 61:102242

Article  CAS  Google Scholar 

Dighe S, Jog S, Momin M, Sawarkar S, Omri A (2024) Intranasal drug delivery by nanotechnology: advances in and challenges for Alzheimer’s disease management. Pharmaceutics 16:58

Article  CAS  Google Scholar 

Eloy JO, Petrilli R, Trevizan LNF, Chorilli M (2017) Immunoliposomes: a review on functionalization strategies and targets for drug delivery. Colloids Surf B 159:454–467

Article  CAS  Google Scholar 

Espinoza LC, Vacacela M, Clares B, Garcia ML, Fabrega M-J, Calpena AC (2018) Development of a nasal donepezil-loaded microemulsion for the treatment of Alzheimer’s disease: in vitro and ex vivo characterization. CNS Neurol Disord Drug Targets 17:43–53

Article  PubMed  CAS  Google Scholar 

Esquer A, Blanc F, Collongues N (2023) Immunotherapies targeting amyloid and tau protein in Alzheimer’s disease: should we move away from diseases and focus on biological targets? A systematic review and expert opinion. Neurol Therapy 12:1883–1907

Article  Google Scholar 

Fonseca LC, Lopes JA, Vieira J, Viegas C, Oliveira CS, Hartmann RP, Fonte P (2021) Intranasal drug delivery for treatment of Alzheimer’s disease. Drug Deliv Transl Res 11:411–425

Article  PubMed  Google Scholar 

Frings L, Blazhenets G, Binder R, Bormann T, Hellwig S, Meyer PT (2023) More extensive hypometabolism and higher mortality risk in patients with right- than left-predominant neurodegeneration of the anterior temporal lobe. Alz Res Therapy 15:11